Stereotactic ablative radiotherapy in the treatment of low and intermediate risk prostate cancer: Is there an optimal dose?

[1]  Liying Zhang,et al.  Predictive Parameters of Symptomatic Hematochezia Following 5-Fraction Gantry-Based SABR in Prostate Cancer. , 2016, International journal of radiation oncology, biology, physics.

[2]  Liying Zhang,et al.  Dose-escalation of five-fraction SABR in prostate cancer: Toxicity comparison of two prospective trials. , 2016, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[3]  Nicholas G Zaorsky,et al.  What is the ideal radiotherapy dose to treat prostate cancer? A meta-analysis of biologically equivalent dose escalation. , 2015, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[4]  Hans T. Chung,et al.  High dose-rate brachytherapy boost for intermediate risk prostate cancer: Long-term outcomes of two different treatment schedules and early biochemical predictors of success. , 2015, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[5]  H. Sandler,et al.  A randomized trial of 79.2Gy versus 70.2Gy radiation therapy (RT) for localized prostate cancer. , 2015 .

[6]  Liying Zhang,et al.  PATRIOT Trial: Randomized phase II study of prostate stereotactic body radiotherapy comparing 11 versus 29 days overall treatment time. , 2015 .

[7]  Guangjun Li,et al.  High dose versus conventional dose in external beam radiotherapy of prostate cancer: a meta-analysis of long-term follow-up , 2015, Journal of Cancer Research and Clinical Oncology.

[8]  S. Siva,et al.  Stereotactic body radiotherapy for primary prostate cancer: A systematic review , 2014, Journal of medical imaging and radiation oncology.

[9]  Josephine Kang,et al.  Quality of Life and Toxicity after SBRT for Organ-Confined Prostate Cancer, a 7-Year Study , 2014, Front. Oncol..

[10]  Constantine Mantz,et al.  A Phase II Trial of Stereotactic Ablative Body Radiotherapy for Low-Risk Prostate Cancer Using a Non-Robotic Linear Accelerator and Real-Time Target Tracking: Report of Toxicity, Quality of Life, and Disease Control Outcomes with 5-Year Minimum Follow-Up , 2014, Front. Oncol..

[11]  Josephine Kang,et al.  Stereotactic Body Radiotherapy as Treatment for Organ Confined Low- and Intermediate-Risk Prostate Carcinoma, a 7-Year Study , 2014, Front. Oncol..

[12]  A. Katz,et al.  Stereotactic body radiotherapy with or without external beam radiation as treatment for organ confined high-risk prostate carcinoma: a six year study , 2014, Radiation Oncology.

[13]  M. Leopoldo,et al.  Small and Innovative Molecules as New Strategy to Revert MDR , 2013, Front. Oncol..

[14]  W. J. Morris,et al.  Prostate-specific antigen at 4 to 5 years after low-dose-rate prostate brachytherapy is a strong predictor of disease-free survival. , 2014, International journal of radiation oncology, biology, physics.

[15]  Jason Wang,et al.  Stereotactic body radiotherapy for localized prostate cancer: pooled analysis from a multi-institutional consortium of prospective phase II trials. , 2013, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[16]  Liying Zhang,et al.  Prostate stereotactic ablative body radiotherapy using a standard linear accelerator: toxicity, biochemical, and pathological outcomes. , 2013, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[17]  P. Cheung,et al.  Intra-fraction motion during extreme hypofractionated radiotherapy of the prostate using pre- and post-treatment imaging. , 2012, Clinical oncology (Royal College of Radiologists (Great Britain)).

[18]  James D Brooks,et al.  Long-term outcomes from a prospective trial of stereotactic body radiotherapy for low-risk prostate cancer. , 2012, International journal of radiation oncology, biology, physics.

[19]  G. Viani,et al.  Higher-than-conventional radiation doses in localized prostate cancer treatment: a meta-analysis of randomized, controlled trials. , 2009, International journal of radiation oncology, biology, physics.

[20]  Joachim Widder,et al.  Recommendations for implementing stereotactic radiotherapy in peripheral stage IA non-small cell lung cancer: report from the Quality Assurance Working Party of the randomised phase III ROSEL study , 2009, Radiation oncology.

[21]  C. Lawton.  Update of Dutch Multicenter Dose-Escalation Trial of Radiotherapy for Localized Prostate Cancer , 2009 .

[22]  Zoran Bursac,et al.  Purposeful selection of variables in logistic regression , 2008, Source Code for Biology and Medicine.

[23]  Yoshiya Yamada,et al.  Long-term results of conformal radiotherapy for prostate cancer: impact of dose escalation on biochemical tumor control and distant metastases-free survival outcomes. , 2008, International journal of radiation oncology, biology, physics.

[24]  Haoran Jin,et al.  Virtual HDR CyberKnife treatment for localized prostatic carcinoma: dosimetry comparison with HDR brachytherapy and preliminary clinical observations. , 2008, International journal of radiation oncology, biology, physics.

[25]  M. Parmar,et al.  Escalated-dose versus standard-dose conformal radiotherapy in prostate cancer: first results from the MRC RT01 randomised controlled trial. , 2007, The Lancet. Oncology.

[26]  C. Fuller,et al.  Early prostate‐specific antigen (PSA) kinetics following prostate carcinoma radiotherapy , 2004, Cancer.

[27]  F. Greene.  AJCC cancer staging handbook , 2002 .